SPRY · ARS Pharmaceuticals, Inc.

The thesis

ARS Pharmaceuticals sells one product, the needle-free epinephrine spray neffy. The case for the shares remains unconfirmed: sales are rising, but the insurance-coverage catalyst that was meant to speed them up did not arrive. The Q3 2026 report, listed by an earnings calendar for 10 November 2026 and not yet confirmed by the company, settles whether revenue growth and lower spending can restore it.

The narrative is dead in its original form: ARS said on 24 June 2026 that no new commercial formulary additions or coverage decisions had been issued for neffy in the latest cycle. The shares closed at $4.32 on 22 October 2026, down 25.0% over three months and 66.9% below the 52-week high of $13.06 (adjusted daily closes). That close is above the $4.23 recorded on 9 October 2026, so the shares have steadied but not recovered. No company announcement dated after the 11 September 2026 insider notices turned up in October.

U.S. neffy net product revenue rose from $17.5 million in Q1 2026 to $26.2 million in Q2 2026, according to the company's results of 13 August 2026. Two quarters are too small a sample to call a durable trend, so no conclusion is drawn from them.

Bullish and bearish views on ARS Pharmaceuticals, Inc.

The bull case on ARS Pharmaceuticals, Inc. (SPRY), in brief: U.S. revenue is growing sequentially. The bear case: The access catalyst missed its date.

Bull case

• U.S. revenue is growing sequentially. ARS reported $26.2 million of U.S. neffy net product revenue in Q2 2026 against $17.5 million in Q1 2026, and total Q2 revenue of $33.7 million (13 August 2026 results). A Q3 figure above $26.2 million would extend the sequence.
• Targeted accounts show higher share. The company reported 8% U.S. epinephrine share in field-targeted accounts and 5% overall for Q2 2026. Management has refocused spending on high-volume prescribers instead of broad consumer advertising.
• Spending is being cut. On 24 June 2026 ARS lowered 2026 cash operating expense guidance to $248 million and reaffirmed cash-flow breakeven in 2027. On 13 August 2026 it guided second-half cash selling, general and administrative plus research and development expense to $100–110 million.
• Analyst targets sit far above the price. Cantor Fitzgerald raised its target to $30 with an Overweight rating on 28 May 2026, and StockAnalysis lists an average 12-month target of $23.25 from four analysts as of 22 October 2026. Those targets pre-date most of the decline.

Bear case

• The access catalyst missed its date. The 24 June 2026 company update said no new commercial formulary additions or coverage decisions had been issued. Plaintiff law-firm notices on the pending class action describe a missed CVS Caremark formulary date that analysts had not expected to slip.
• Losses are large against the cash balance. ARS reported a $62.3 million net loss for Q2 2026 and $143.8 million of cash, equivalents and short-term investments at 30 June 2026. The goal of cash-flow breakeven by end-2027 has not yet been shown in a reported quarter.
• Insiders filed to sell. Two Form 144 notices for proposed restricted-stock sales appeared on 11 September 2026, during the decline.
• One product carries the revenue. A payer decision, safety headline or supply problem would hit the whole revenue line.
• Management is new. CEO Donn Casale's first earnings call was 13 August 2026 and Chief Commercial Officer Meg Smith started 17 August 2026, so neither has yet reported a quarter under the revised plan.

Price setup

The shares closed at $4.32 on 22 October 2026, against $4.08 on 25 September 2026 and $4.23 on 9 October 2026 (adjusted daily closes). That is 66.9% below the 52-week high of $13.06. The 14-day Relative Strength Index, a momentum gauge where 30 is oversold and 70 overbought, reads 56.8, so the shares are neither stretched nor washed out.

Crowding evidence is limited. The shares trade far below their high rather than above a rising average, and the only dated selling evidence is the two Form 144 notices of 11 September 2026. The imminent Q3 earnings date is the one crowding factor: the report arrives roughly 19 days after the 22 October 2026 close.

Benzinga's earnings page lists consensus Q3 2026 revenue of $43.2 million, against $33.7 million of total revenue in Q2. That consensus sets the bar for the report, and a total near $33.7 million would read as a miss against it.

Catalysts, next 30 days

• ~10 November 2026, est. Q3 2026 results and call. An earnings-calendar listing shows 8:30 a.m. on that date; the company has not confirmed it. The prior-year Q3 report came on 10 November 2025. Key items: U.S. neffy revenue against Q2's $26.2 million, the $100–110 million second-half expense guide, and the cash balance against $143.8 million at 30 June 2026.

Elapsed catalysts

• Unscheduled — any commercial formulary or coverage announcement. None had been reported as of 22 October 2026. An addition would be the first evidence of repair after the missed July cycle. (passed 15d ago)

What would change the view

The case breaks if the shares close below $3.80 or if the Q3 2026 report shows U.S. neffy revenue at or below Q2's $26.2 million. Second-half cash expense guidance above $110 million, withdrawal of the 2027 breakeven timetable, or an equity offering would also break it.

The rating moves up if Q3 U.S. neffy revenue clearly exceeds $26.2 million while the expense guide holds, or if a commercial formulary addition is announced. Further Form 144 or Form 4 sale filings after 11 September 2026 would add weight to the bear case.

What it trades with

ARS trades on company-specific access and sales news for a single product rather than on a sector move. Its revenue depends on U.S. payer decisions and on prescriber adoption against other epinephrine products, including auto-injectors. Ex-U.S. income reaches ARS through ALK-Abelló as supply revenue, milestones and royalties.

Small, cash-burning healthcare companies as a group are sensitive to financing conditions, because an equity raise is the standing risk when losses exceed cash generation. No other company shares neffy's revenue drivers.